Abstracts tagged "rheumatic disease and tuberculosis"

Abstract Number: 1235 • 2018 ACR/ARHP Annual Meeting
Isoniazid Monotherapy As a Prophylaxis for Tuberculosis in Patients with Rheumatic Diseases Exposed to Prolonged, High-Dose Glucocorticoids
Jun Won Park¹, Jeffrey R. Curtis², Hajeong Lee³, Yeong Wook Song⁴ and Eun Bong Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁴Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Although use of glucocorticoid increases the risk of tuberculosis (TB) disease, there has been few studies investigating its incidence and risk/benefit assessment of the…
Abstract Number: 2409 • 2017 ACR/ARHP Annual Meeting
Older Age and Male Gender Are Independent Predictors of Quantiferon Positivity Among Adult Rheumatic Patients in a Tertiary Care Center from a BCG Vaccinated Country: Hur-BIO Single Center Real Life Results
Emrah Seyhoglu¹, Oguz Abdullah Uyaroglu¹, Abdulsamet Erden², Levent Kilic², Berkan Armagan², Alper Sari², Omer Karadag², Sule Apras Bilgen², Ali Akdogan², Ihsan Ertenli², Umut Kalyoncu² and Sedat Kiraz², ¹Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: TNF-α inhibitors increase the risk of emergence of active tuberculosis (TB). Screening rheumatic patients for latent TB is a necessity before initiation of biological…
Abstract Number: 1363 • 2013 ACR/ARHP Annual Meeting
Active Tuberculosis Risk With Tumor Necrosis Factor Inhibitors After Treating Latent Tuberculosis -a 7-Year Retrospective Observational Study
Minkyung Kwon¹, Mindong Sung¹, Yong-Jin Kwon¹, Young Goo Song¹, Sang-Won Lee², Min-Chan Park¹, Yong-Beom Park¹, Soo-Kon Lee¹ and Jason Jungsik Song¹, ¹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ²Department of Internal Medicine, Yonsei University College of Medicine, Seoul, NV, South Korea
Background/Purpose: Active tuberculosis (TB) risk increases during anti-tumor necrosis factor (TNF) therapy and latent TB infection (LTBI) screening is recommended in potential TNF inhibitor users.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].